Display options
Cite
Acharya S, Pillai K, Francis A, et al. Kasabach merritt syndrome: management with interferon. Indian J Dermatol. 2010;55(3):281-3doi: 10.4103/0019-5154.70705.
Acharya, S., Pillai, K., Francis, A., Criton, S., & Parvathi, V. K. (2010). Kasabach merritt syndrome: management with interferon. Indian journal of dermatology, 55(3), 281-3. https://doi.org/10.4103/0019-5154.70705
Acharya, Sandhya, et al. "Kasabach merritt syndrome: management with interferon." Indian journal of dermatology vol. 55,3 (2010): 281-3. doi: https://doi.org/10.4103/0019-5154.70705
Acharya S, Pillai K, Francis A, Criton S, Parvathi VK. Kasabach merritt syndrome: management with interferon. Indian J Dermatol. 2010 Jul-Sep;55(3):281-3. doi: 10.4103/0019-5154.70705. PMID: 21063527; PMCID: PMC2965921.
Copy Download .nbib Format: NLM
Share it on

Indian J Dermatol. 2010 Jul-Sep;55(3):281-3. doi: 10.4103/0019-5154.70705.

Kasabach merritt syndrome: management with interferon.

Indian journal of dermatology

Sandhya Acharya, Kalyani Pillai, Abel Francis, S Criton, V K Parvathi

Affiliations

  1. Department of Dermatology, Amala Institute of Medical Sciences,(AIMS), Thrissur, Kerala, India.

PMID: 21063527 PMCID: PMC2965921 DOI: 10.4103/0019-5154.70705

Abstract

Kasabach Merritt Syndrome (KMS) is a rare, locally aggressive, vascular tumor. The objectives of treatment of KMS are to prevent bleeding from consumptive coagulopathy and induce vascular tumor regression. A 14-month old female child was brought with a reddish lesion on the left scapular area noticed at birth, which suddenly increased in size since 3 days. Hemogram revealed anemia severe thrombocytopenia, prolongation of bleeding, clotting time and increased fibrin degradable products, suggestive of KMS. Coagulopathy was managed by transfusing fresh frozen plasma and platelets. Oral prednisolone up to 5mg/kg/day for four weeks yielded no effect on thrombocytopenia or regression of tumor size. Embolization of feeding artery was attempted but not feasible. We used Interferon -alpha- 2b (IFN α 2b), in a dosage of 3million IU/m(2) /day subcutaneously. Within a month the platelet count increased and the vascular tumor started regressing. This case signifies the importance of step wise management of KMS.

Keywords: Kasabach Merritt syndrome; coagulopathy; interferon α 2b

References

  1. Pediatr Int. 2000 Dec;42(6):620-4 - PubMed
  2. J R Soc Med. 1993 Apr;86(4):231-2 - PubMed
  3. J Am Acad Dermatol. 1998 May;38(5 Pt 2):799-802 - PubMed
  4. J Pediatr. 1999 Dec;135(6):782-5 - PubMed
  5. Int J Dermatol. 2003 Sep;42(9):741-8 - PubMed
  6. Br J Haematol. 2001 Mar;112(4):851-62 - PubMed
  7. J Pediatr. 1997 Apr;130(4):631-40 - PubMed
  8. N Engl J Med. 1992 May 28;326(22):1456-63 - PubMed
  9. Pediatrics. 1987 Jun;79(6):971-80 - PubMed

Publication Types